Segall Bryant & Hamill LLC Invests $2.07 Million in Becton, Dickinson and Company $BDX

Segall Bryant & Hamill LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the first quarter, HoldingsChannel reports. The fund acquired 12,709 shares of the medical instruments supplier’s stock, valued at approximately $2,074,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. CTC Alternative Strategies Ltd. bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $393,000. Liontrust Investment Partners LLP increased its position in shares of Becton, Dickinson and Company by 18.0% in the 1st quarter. Liontrust Investment Partners LLP now owns 645,308 shares of the medical instruments supplier’s stock valued at $101,462,000 after buying an additional 98,212 shares in the last quarter. Western Wealth Management LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at $41,000. Edgestream Partners L.P. raised its stake in Becton, Dickinson and Company by 38.7% during the 1st quarter. Edgestream Partners L.P. now owns 2,648 shares of the medical instruments supplier’s stock worth $416,000 after buying an additional 739 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in Becton, Dickinson and Company by 11.0% during the first quarter. Janus Henderson Group PLC now owns 467,396 shares of the medical instruments supplier’s stock worth $73,485,000 after acquiring an additional 46,157 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. The trade was a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,189 shares of company stock valued at $765,661 over the last ninety days. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $170.15 on Wednesday. The stock has a 50-day moving average price of $152.74 and a two-hundred day moving average price of $162.89. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market cap of $46.88 billion, a PE ratio of 43.08, a price-to-earnings-growth ratio of 12.13 and a beta of 0.19. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 12.53 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Barclays boosted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Piper Sandler cut their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $180.93.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.